LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus

This study has been terminated.

Sponsored by:	Sanofi-Aventis
Information provided by:	Sanofi-Aventis
ClinicalTrials.gov Identifier:	NCT00349986

Purpose

The rationale of the study is to determine:

the first dose and the titration of basal insulin
the exact daily time administration of basal insulin in poorly controlled type II diabetic patients.

Condition	Intervention	Phase
Diabetes Mellitus, Type 2	Drug: Insuline glargine	Phase IV

MedlinePlus related topics: Diabetes

Drug Information available for: Insulin Insulin glargine

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study
Official Title:	The Determination of the First Dose and the Optimal Time of Administration of Insulin Glargine Combined With Oral Antidiabetic Drug in Poorly Controlled Type II Diabetic Patients

Further study details as provided by Sanofi-Aventis:

Primary Outcome Measures:

Enrollment:	7
Study Start Date:	May 2006
Primary Completion Date:	March 2007 (Final data collection date for primary outcome measure)

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00349986

Locations

Sponsors and Collaborators

Sanofi-Aventis

Investigators

Study Director:

László Erős, MD

Sanofi-Aventis

More Information

Study results This link exits the ClinicalTrials.gov site

Responsible Party:	Sanofi-aventis ( Medical Affairs Study Director )
Study ID Numbers:	HOE901_4059
Study First Received:	July 7, 2006
Last Updated:	September 28, 2008
ClinicalTrials.gov Identifier:	NCT00349986
Health Authority:	Hungary: National Institute of Pharmacy

Study placed in the following topic categories:

Metabolic Diseases
Diabetes Mellitus, Type 2
Glargine
Diabetes Mellitus
Endocrine System Diseases

Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders
Insulin

Additional relevant MeSH terms:

Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009